AI Terminal
NUFORMIX PLC
Regulatory Filings • Nov 4, 2022
4941_rns_2022-11-04_1d6e20c1-9c08-477d-aff9-5f9c18c40c5a.html
Regulatory Filings
Open in ViewerOpens in native device viewer
National Storage Mechanism | Additional information 
RNS Number : 2785F
Nuformix PLC
04 November 2022
REACH
4 November 2022
Nuformix plc
("Nuformix" or the "Company" or the "Group")
Investor Webinar
Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, is pleased to announce that the Company will be hosting an online presentation and Q&A session at 5.30 p.m. GMT on Wednesday 9 November 2022. This session is open to all existing and prospective shareholders. Those who wish to attend should register via the following link where they will be provided with access details:
https://us02web.zoom.us/webinar/register/WN_S2zoC1BuS8KLOVZwAhYHNQ
Participants will have the opportunity to submit questions during the session, but questions are welcomed in advance and may be submitted to: [email protected]
Enquiries:
| Nuformix plc | |
| Dr Dan Gooding, Executive Director | Via IFC Advisory |
| Stanford Capital Partners Limited | |
| Tom Price / Patrick Claridge (Corporate Finance) | +44 (0) 20 3650 3650 |
| John Howes (Corporate Broking) | +44 (0) 20 3650 3652 |
| IFC Advisory Limited | |
| Tim Metcalfe Zach Cohen |
+44 (0) 20 3934 6630 [email protected] |
About Nuformix
Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing and patenting novel drug forms, with improved physical properties, to develop new products in new indications that are, importantly, differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities. Nuformix has a pipeline of pre-clinical assets with potential for significant value and early licensing opportunities.
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
NRAUPGBAGUPPGQW